Get-up and Go: Adynamic Bone Disease in Chronic Kidney Disease Patient

被引:0
|
作者
Magbri, Awad [1 ]
El-Magbri, Mariam [1 ]
Hernandez, Pablo Abrego [1 ]
机构
[1] Marshfield Clin Fdn Med Res & Educ, Weston, WI 54449 USA
关键词
Adynamic bone disease; Secondary hyperparathyroidism; Chronic kidney disease; Vitamin D analogs; Hypercalcemia; Peritoneal dialysis; STAGE RENAL-FAILURE; HEMODIALYSIS-PATIENTS; DIALYSIS PATIENTS; ALKALINE-PHOSPHATASE; CALCIUM-CARBONATE; MINERAL DENSITY; OSTEODYSTROPHY; TURNOVER; FRACTURES; TERIPARATIDE;
D O I
10.51847/suXosREK5t
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We reported a case of adynamic bone disease (ABD) in an older woman with chronic kidney disease, stage-4 (CKD-4), with an estimate of 29ml/min glomerular filtration rate (eGFR). Similarly, the patient presented with bone pain and osteoporosis as well as intact parathyroid hormone (PTH) was suppressed (<6ng/dl) secondary to the use of vitamin D analogs for secondary hyperparathyroidism (SHPT) of CKD. Furthermore, the hypercalcemia of (11.1 mg/dl), and her dual-energy X-ray absorptiometry (DEXA) scan showed bone mineral density (BMD) of-2.6 SD. Low levels of PTH induces a state of low turnover bone disease. Numerous, factors are involved in this process in patients with ESRD on dialysis. Among these factors are the use of vitamin D analogs, the ill-effects high calcium baths, treatment of osteoporosis with bisphosphonates, etc. All these factors can singly or in combination suppress PTH and render the bone resistant to its action with the end results of a dynamic bone disease. The vitamin D analogs were stopped to allow recovery of the PTH and activation of the osteocytes and osteoblasts. Six months after stopping active vitamin D analogs, her hypercalcemia was resolved, and the PTH increased to 172 ng/dl. Her bone pain has resolved.
引用
收藏
页码:11 / 15
页数:5
相关论文
共 50 条
  • [31] Bone imaging in patient with chronic kidney disease: A new tool for managing renal osteodystrophy?
    Bacchetta, Justine
    Boutroy, Stephanie
    Delmas, Pierre
    Fouque, Denis
    NEPHROLOGIE & THERAPEUTIQUE, 2009, 5 (01): : 25 - 33
  • [32] Interventions for bone disease in children with chronic kidney disease
    Geary, Denis F.
    Hodson, Elisabeth M.
    Craig, Jonathan C.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2010, (01):
  • [33] Hypercalcemia and pancreatitis in a child with adynamic bone disease
    Alexies Osorio
    F. Glen Seidel
    Bradley A. Warady
    Pediatric Nephrology, 1997, 11 : 223 - 225
  • [34] Bone Quality in Chronic Kidney Disease Patients: Current Concepts and Future Directions - Part II
    Asadipooya, Kamyar
    Abdalbary, Mohamed
    Ahmad, Yahya
    Kakani, Elijah
    Monier-Faugere, Marie-Claude
    El-Husseini, Amr
    KIDNEY DISEASES, 2021, 7 (05) : 359 - 371
  • [35] Crosstalk between bone and muscle in chronic kidney disease
    Wong, Limy
    McMahon, Lawrence P.
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [36] Pharmacotherapy of chronic kidney disease and mineral bone disorder
    Barreto, Fellype Carvalho
    de Oliveira, Rodrigo Azevedo
    Oliveira, Rodrigo Bueno
    Jorgetti, Vanda
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (17) : 2627 - 2640
  • [37] Changing bone patterns with progression of chronic kidney disease
    Drueeke, Tilman B.
    Massy, Ziad A.
    KIDNEY INTERNATIONAL, 2016, 89 (02) : 289 - 302
  • [38] Update on Mineral and Bone Disorders in Chronic Kidney Disease
    Foster, Jonathan D.
    VETERINARY CLINICS OF NORTH AMERICA-SMALL ANIMAL PRACTICE, 2016, 46 (06) : 1131 - +
  • [39] Teriparatide treatment in a heart transplant patient with a chronic kidney disease and a low-turnover bone disease: a case report
    Fahrleitner-Pammer, A.
    Wagner, D.
    Krisper, P.
    Amrein, K.
    Dimai, H.
    OSTEOPOROSIS INTERNATIONAL, 2017, 28 (03) : 1149 - 1152
  • [40] Treatment of Hemodialysis-Associated Adynamic Bone Disease with Teriparatide (PTH1-34): A Pilot Study
    Cejka, Daniel
    Kodras, Katharina
    Bader, Till
    Haas, Martin
    KIDNEY & BLOOD PRESSURE RESEARCH, 2010, 33 (03) : 221 - 226